3
Clinical Trials associated with JMT-601评价JMT601联合不同化疗方案治疗CD20阳性弥漫性大B细胞淋巴瘤参与者的有效性和安全性的多中心、Ⅱ期临床研究
[Translation] A multicenter, phase II clinical study to evaluate the efficacy and safety of JMT601 combined with different chemotherapy regimens in the treatment of participants with CD20-positive diffuse large B-cell lymphoma
评价JMT601联合不同治疗方案治疗CD20+ DLBCL参与者的耐受性和疗效
[Translation] To evaluate the tolerability and efficacy of JMT601 in combination with different treatment regimens in participants with CD20+ DLBCL
试验专业题目 评价JMT601 治疗复发/难治性CD20 阳性B 细胞非霍奇金淋巴瘤的Ⅰ 期临床研究
[Translation] A Phase I clinical study evaluating JMT601 for the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
主要目的:评价JMT601 注射液治疗复发/难治性CD20 阳性B 细胞非霍奇金淋巴瘤的安全性和耐受性,确定II 期研究推荐剂量(RP2D);
次要目的:1.评价JMT601注射液在复发/难治性CD20阳性B细胞非霍奇金淋巴瘤患者中的疗效;2.JMT601注射液药物代谢动力学特征;3.评价JMT601注射液的免疫原性;4.生物标志物的变化情况。
[Translation] Primary objective: To evaluate the safety and tolerability of JMT601 injection in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma and determine the recommended dose (RP2D) for Phase II studies;
Secondary objectives: 1. To evaluate the efficacy of JMT601 injection in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma; 2. Pharmacokinetic characteristics of JMT601 injection; 3. To evaluate the immunogenicity of JMT601 injection; 4. Changes in biomarkers.
Phase 1/2, Multicenter, First-In-Human, Dose Escalation and Dose Expansion Study of CPO107 Administered Intravenously to Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available.
100 Clinical Results associated with JMT-601
100 Translational Medicine associated with JMT-601
100 Patents (Medical) associated with JMT-601
100 Deals associated with JMT-601